The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers

Background: Camrelizumab (SHR1210) is a high-affinity, humanized immunoglobulin programmed cell death 1 (PD-1) monoclonal antibody. It was developed by Jiangsu Hengrui Medicine Co. Ltd. and has been approved for relapsed or refractory classical Hodgkin lymphoma patients and hepatocellular carcinoma...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Front Pharmacol
Hauptverfasser: Wang, Kunlun, Li, Bingxu, Li, Mengxi, Li, Shenglei, Yang, Hui, Yuan, Ling
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2020
Schlagworte:
Pharmacology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7609870/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.568477
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge